Veracyte to Present Expanded Decipher Classifier Data at 2026 ASCO GU Symposium
Veracyte will present new Decipher genomic classifier data at the 2026 ASCO Genitourinary Cancers Symposium in February, highlighting expanded clinical validation studies in prostate cancer. The presentations aim to reinforce Decipher’s role in risk stratification and treatment decision-making for urologic oncology.
1. Symposium Presentation Details
Veracyte plans to showcase new Decipher genomic classifier data at the 2026 ASCO Genitourinary Cancers Symposium in February, featuring multiple clinical validation studies in prostate cancer risk assessment and treatment stratification. Presentations will include both oral and poster sessions designed to highlight Decipher’s expanded data portfolio.
2. Strategic Implications
By presenting robust clinical outcomes at a leading oncology meeting, Veracyte aims to strengthen Decipher’s credibility among oncologists and urologists, potentially accelerating clinical adoption. Success at this high-profile event could advance reimbursement discussions and support future revenue growth for the diagnostic platform.